INTERBRI · CHINA MARKET ACCESS FOR MEDICAL DEVICES China-focused support. Clear scope. Accountable coordination.
Class III · Registration

Class III Medical Device Registration Requirements and Dossier

Registration managementAccepted and reviewed by NMPAHigher risk

Class III medical devices are of higher risk and require special measures to strictly control safety and effectiveness, so they are subject to registration management, accepted and reviewed by the National Medical Products Administration (NMPA), with certificates valid for 5 years. Class III products are typically implantable, interventional or life-supporting, and the regulatory expectations are the strictest of the three classes — documentation, quality systems and clinical evaluation all deserve a higher standard of preparation.

I. The Six Sections of a Registration Dossier

As with Class II, the registration dossier is organized under six primary headings:

Table: I. The Six Sections of a Registration Dossier
SectionMain Contents
1. Regulatory InformationTable of contents, application form, glossary and abbreviations, product list, associated documents, pre-submission communications with the authority, declaration of conformity
2. Overview DocumentationOverview, product description, intended use and contraindications, marketing history, other explanations
3. Non-clinical DocumentationRisk management documentation, essential principles of safety and performance checklist, product technical requirements and test reports, research documentation, non-clinical literature, stability studies
4. Clinical Evaluation DocumentationClinical evaluation documentation (route selection below)
5. Instructions for Use and LabelingInstructions for use, labeling samples
6. Quality Management System DocumentationOverview, manufacturing information, QMS procedures, management responsibility, resource management, product realization, measurement/analysis/improvement procedures, QMS verification documents

II. What Makes Class III Different

  • QMS verification of overseas manufacturing sites — within the quality management system documentation, the "QMS verification documents" section matters most for imported Class III products: review typically involves registration quality management system verification arrangements for the overseas manufacturing site, potentially including on-site audits. Prepare your QMS documentation and site condition early, and reserve time for verification;
  • Stricter clinical evaluation expectations — higher-risk products are more likely to need clinical trials; eligible products may still leverage overseas clinical data under the regulations, but ethical and scientific requirements must be checked item by item;
  • Directly accepted and reviewed by NMPA — all Class III products go through NMPA regardless of origin; review depth and communication differ from Class II, making pre-submission pathway planning and early engagement more valuable.
Class III preparation cycles are counted in months — sometimes years. Moving QMS verification, notarization/translation and clinical-evaluation planning to the front is the most effective way to shorten the overall timeline.

III. Formal Requirements for Imported Products

Imported Class III dossiers follow the same formal requirements, centred on four threads: contents & binding (bound in catalogue order, one copy, two for the Product Technical Requirements, A4 without alterations), Chinese language (all documents except associated documents in Chinese, foreign supporting documents with agent-stamped translations plus originals), signatures & notarization (original-language documents signed by the overseas applicant, Chinese documents by the domestic agent; associated documents, declaration of conformity, instructions and labels notarized in the applicant's jurisdiction), and electronic documents (application form, product technical requirements, overview documentation, non-clinical study overview, instructions for use as editable Word files; clinical trial databases by file type).

For the full formal-requirements list, see Class II Medical Devices: Registration Documentation & Requirements.

IV. Process & Timeline Expectations

A typical Class III route runs: preparation → acceptance → technical review (with correction rounds) → registration QMS verification (where applicable) → administrative approval → certificate. Statutory time limits are governed by current provisions, but the actual timeline depends largely on dossier quality and the number of correction rounds — the more complete the preparation, the fewer the round-trips and the more controllable the pace. Before launching, complete three pieces of homework: classification confirmation, clinical-evaluation route selection, and a QMS gap assessment.

V. How INTERBRI Helps

  • Submission planning — sequencing documentation, QMS verification and clinical evaluation based on product risk and marketing history;
  • Documentation system — building the dossier around the six sections, checking consistency and coordinating translation;
  • QMS verification readiness — helping organise QMS documentation and overseas-site verification preparations;
  • Submission & follow-up — coordinating submission, tracking acceptance, review and corrections, with prompt updates.

Planning a Class III registration?

Class III is a long game — the earlier you plan, the more options you keep. Send us your product information and let's talk through your submission plan.

About Our Initial Registration Service
This page is compiled from current regulatory requirements for reference only and does not constitute legal advice; the specific requirements are subject to the latest provisions of China's medical device authorities and the documents applicable at acceptance.

Examples of Class III medical devices in China

Class III covers higher-risk devices that need special control. Illustrative examples include: cardiac stents, pacemakers and implantable defibrillators; artificial joints and intraocular lenses; vascular catheters and other implantable devices; and large imaging equipment such as CT and MRI scanners and certain ventilators. These examples are illustrative; the official Classification Catalogue decides the actual class. Where uncertainty exists, a classification determination is the reliable route. See our China medical devices overview.

Clinical evaluation vs. clinical trial for Class III devices

Class III devices must be supported by clinical evaluation, but a clinical evaluation is not the same as a clinical trial. Under Decree No. 739, Article 25, clinical evaluation may be satisfied either by analysing literature and clinical data of a predicate (same-type) device, or by conducting a clinical trial; a trial is required only when existing data are insufficient to demonstrate safety and effectiveness. For high-risk Class III devices, a clinical trial must be approved by NMPA before it begins (Decree No. 739, Article 27); the approval decision is made within 60 days (SAMR Decree No. 47, Article 40). The choice between evaluation routes is decided on the product and its data, and should be confirmed case by case. See our clinical evaluation guide.

How to confirm your device’s management class

China sorts medical devices into three classes by risk. The authoritative source is the official Medical Device Classification Catalogue published by NMPA, which lists many product families together with their management class and example names. If your product is not listed, or its class is uncertain, you can apply for a classification determination (分类界定): new or unlisted products and uncertain imported products are submitted to the NMPA Standardization and Management Center, while uncertain domestic products go to the provincial authority. In practice, check the catalogue first and, where it is unclear, confirm the route with the competent authority before preparing the dossier. Our China medical devices overview and the classification catalogue guide set out the working approach.

Frequently asked questions

QDoes Class III always require a clinical trial?

No. Class III devices must undergo clinical evaluation, but clinical evaluation can be satisfied either by analysing literature and clinical data of a predicate device, or by conducting a clinical trial. A trial is required only when existing data are insufficient (Decree No. 739, Article 25). For high-risk Class III devices, a clinical trial must be approved by NMPA before it starts (Decree No. 739, Article 27).

QWhat is the difference between clinical evaluation and a clinical trial?

Clinical evaluation is the broader process of demonstrating safety and effectiveness — it may rely on predicate-device literature/data or on a purpose-conducted trial. A clinical trial is a specific study conducted in accredited institutions under the clinical-trial quality standard. See our clinical evaluation guide.

QWhich authority reviews Class III registration?

NMPA reviews and approves domestic Class III and all imported Class II/III devices; the Center for Medical Device Evaluation (CMDE) performs the technical review. See our initial registration service.

QHow long does Class III registration take?

Statutory time limits apply to discrete administrative steps — the application is transferred to technical review within three working days of acceptance, and a decision is made within 20 working days after the review opinion is received; a clinical-trial approval decision is made within 60 days. These are not the total project duration: the overall timeline depends on dossier completeness, QMS readiness, clinical data and any supplementary-material cycles, and should be confirmed case by case. See our initial registration service.

Back to China Medical Devices